21th September 2017 Mid Cap | Europe | Italy



Update

BUY

Target price: EUR 12.30

Industry:	Software and IT Service
Country:	Italy
ISIN:	IT0001454435
Bloomberg:	TXT:IM
Reuters:	TXTS.MI
Website:	txtgroup.com


Last Price:		11.06
	High	Low
Price 52 W.:	13.20	6.95
Market Cap. (EURm)		129.31
No. of Shares		11.69

Shareholders

4CV PTE	25.62%
A. Braga Illa	13.96%
Treasury shares	9.92%
Kabouter LLC	7.96%
Allianz GI GmbH	2.31%
Management	7.90%
Float	32.33%

Dividend		
	in EUR	in %
2012	0.40	17.6%
2013	0.20	2.8%
2014	0.25	3.9%
2015	0.25	3.4%
2016	0.30	3.1%

1-year Chart



Analyst:

Dr. Norbert Kalliwoda nk@kalliwoda.com

TXT e-solutions S.p.A.

New growth perspectice after disposal of Aptos

- TXT reported revenues of € 36.1 million in H1 2017,up +8.9% compared to H1 2016 (€ 33.2 million). The growth was manly driven by revenues from Pace GmbH (€ 1.9 million, acquisition and consolidation since April 1, 2016) and organic growth (+3.7%).
- TXT Retail generated € 18.2m, which constituted 504% of group revenues and recorded growth of +2.5% compared to 6M/2016 (previous period: € 17.8m). TXT Retail generated EBITDA of € 1.47m in 6M/17, a margin of 8.1% (vs. the group margin of 9.5%).
- On July 24th TXT signed a contract for the inclusion of its TXT Retail Division to Aptos, Inc. (USA). The agreed price of € 85m will be paid in cash by Aptos.
- Focus on TXT Next with substantial cash on hand, allow the Company to develop aeronautical, the auto industry, transport, and complex industrial systems. We see tremendous potential in these areas. Specifically, we see potential for synergies due to acquisition of PACE in the field of on-board software, flight simulators, and flight training system. Therefore, we regard the deal with Aptos as beneficial for the Company growth.
- Overall, 6M figures came in strong, with top line being in line with our expectations. Some concerns may raise bottom line of the business in 6M/2017, we expected higher number. However, looking forward, we expect the Company's profit yoy momentum to remain positive for the coming quarters.
- Due to some uncertainty regarding the closing deal with Aptos, we leave our estimates unchanged, slightly increasing the target price and therefore setting a 12-month target price at EUR 12.30, with upside around 12% at the current price.

Key Facts

EURm	2012	2013	2014	2015	2016	2017E
Net sales	46.5	52.6	55.9	61.5	69.2	75.9
EBITDA	5.3	6.3	6.8	5.9	8.2	8.8
EBIT	4.2	5.0	5.5	4.8	6.9	7.6
Net income	5.1	4.6	4.2	3.9	5.6	6.0
EPS	0.9	0.4	0.3	0.3	0.5	0.5
BVPS	4.8	2.4	2.2	2.6	2.9	3.2
RoE	19.6%	16.6%	14.4%	11.5%	16.2%	16.1%
EBIT margin	9.1%	9.4%	9.8%	7.8%	10.0%	10.0%

Company Analysis

Content

1.	Profile	3
2.	PACE GmbH (Berlin-Headquartered)	3
3.	SWOT Analysis	4
4.	Valuation	4
a.	WACC	5
b.	DCF-Model	5
5.	Financial results 6M/2017	6
6.	Profitability	7
7.	Outlook	7
8.	Shares	8
9.	Financials	9
a.	Profit and Loss Statement	9
b.	Balance Sheet	10
c.	Cash Flow Statement	11
d.	Financial Ratios	11
Cor	ıtacts	. 13
Dis	claimer	. 13
Ess	ential information, disclosures and disclaimer	. 14

Equity Research

1. Profile

TXT e-solutions SpA is a profitable international software specialist. Headquartered in Milan (Italy), TXT filled an empty space in the supply chain IT solutions, developing planning software solutions in end-to-end retail for the luxury and fashion sector. The company is divided in two business divisions: TXT Retail, which provides IT planning solutions for luxury, fashion, retail and consumer goods, and TXT Next which focus in software for complex operation and manufacturing for aerospace, defence, high-tech and finance.

After the IPO in 2000, TXT invested to become a global supply chain software vendor with a geographic coverage of all main markets. The company has offices in the North America, Germany, France, Spain, the UK and in the Asia Pacific. With organic growth in both the divisions, the company recorded a significant increase in revenues during the years (CAGR +12% in 2010-2016).

2. PACE GmbH (Berlin-Headquartered)

On April 1, 2016, TXT e-solutions completed the acquisition of the Berlin-based Pace GmbH, software providers for the aerospace and aviation industries. The acquisition reinforced TXT Next aerospace business division. Pace performed well in 2015, with consolidated results showing revenues of €7.3m. Net financial position of PACE was positive by €2.3m. PACE has 70 employees mostly in Berlin, with activities in the aerospace hubs of Toulose (F) and Seattle (USA).

TXT bought the 79% of PACE shares directly from its investors (eCAPITAL AG, Strategic European Technologies NV, and IBB Beteiligungsgesellschaft mbH). The acquisition of Pace GmbH completed on 1 April 2016 involved a net disbursement of \leqslant 6.8 million,broken down as follows:

- € 7.7 million already paid upon purchase of 79% of the company's shares;
- an additional € 1.4 million in estimated future payments to exercise the put/call option in 2020-2021 to purchase the remaining 21% of the company's shares; payment of the "Earn-out 2016" and other contractual terms;
- -€ 2.3 million for the net financial benefit arising from the acquisition of Pace, generated by the balance of cash acquired (€ 3.5 million) and financial debtacquired (€ 1.2 million).

The three founders therefore will remain shareholders and managing directors (21% of the capital will be hold by them) and agreed with TXT a put-call option to be exercised in the period 2020-2021.

PACE customer base includes: Maintenance, Repair & Overhaul (MRO) companies, such as Airbus (D and F), Boeing (USA), Lufthansa (D), GE Aviation (USA), Safran Group (F), COMAC (China), Sukhoi (Russia), Embraer (Brasil), Rolls-Royce (UK), Air France & KLM Engineering (F) and Delta Air Lines (USA).

The integration of TXT Next and Pace GmbH might develop further benefits, due to the complementary solutions that TXT Next can integrate in Pace such as the on board software, simulation, training system and advanced manufacturing for aerospace. The joining forces can bring new advanced software solutions and expand the product portfolio for TXT Next clients. TXT Next and Pace will focus on high value niches across the entire value chain in the software aviation industry.

3. SWOT Analysis

Strengths

- Pioneer in the supply chain software for fashion and luxury.
 In TXT Retail division 89% of sales from abroad.
- Self-financed business through profits, free cash flows and growing stock values.
- High entry barriers, given its customized and innovative solutions and well-established relationships.
- Loyal customer base, with well-known clients (i.e. Louis Vuitton (F), Swatch (CH), Adidas (D), Burberry (UK)).
- Net financial position positive for € 5.4m (31 December 2016).
- Solid shareholder base: founder owns almost 14% of the capital, and a significant stakes is owned by co-workers & management.

Opportunities

- Growth in the aerospace segment, given the expertise and international client portfolio acquired with PACE GmbH.
- Business development in North America, Asia and Pacific area. In 2015 a new office was opened in Hong Kong and Singapore.
- Improving revenues mix with higher sales from licenses and maintenance in the retail segments. Monetization of existing clients with new products and service.
- International growth through acquisitions

Weaknesses

- Significant goodwill position, which amount to 52% of equity (31 December 2016).
- Limited presence in emerging markets such as Asia, Pacific, Africa, the Middle East and Latin America. Strong focus in the no-food area.
- Continuous investments in marketing and R&D in order to compete with big players.

Threats

- Uncertainty in the retail fashion and luxury market, given the economic slowdown and industry transformation.
- High competition from larger players.
- Currency risks for the consolidated financial statements as TXT generates more than 20% sales outside the Euro Area, even if revenues are hedged almost perfectly with costs incurred in the same currency.

Source: Dr. Kalliwoda International Research GmbH

4. Valuation

Our valuation is based on a traditional DCF model (100%). We have forecasted the revenues CAGR of 5.3% and average EBIT margin of 10.5% in the period 2017-2020. The WACC (weighted average cost of the capital) remains unchanged to our previous update: risk-free rate 1.4%, market premium 6.0% (expected return minus risk-free ratio), beta equal to 1 and the tax rate of 20.1% (average of the last four years). Assuming that the target capital structure will not change in the subsequent years, the WACC consequently was 6.4%. Our price target based on our DCF-Model is €12.30 per share.

a. WACC

	DCF i	model	
Input		Output	
WACC Calculation		Enterprise value	
Target Capital Structure		Present value of Free Cash Flow	22,5
Debt to Total Capitalization	15,4%		
Equity to Total Capitalization	84,6%	Terminal Value	168
		Discount Factor	8,0
Cost of Equity		Present Value of Terminal Value	127
Risk-free rate	1,4%	% of Enterprise Value	85%
Market risk Premium	6,0%		
Levered Beta	1,00	Enterprise value	149,3
Cost of Equity	7,4%	Less: Total debt	2,2
	•	Plus: Cash and Cash Equi.	7,6
Cost of Debt		Net Debt	5,4
Cost of Debt	1,5%		
Taxes	20,1%		
After Tax Cost of Debt	1,2%	Implied Equity Value	143,9
		Outstanding shares	11,7
WACC	6,4%	Implied share price	12,3
(1) Obtained from Beta and Capital Structure tab		Implied multiples	
(2) Interpolated Yield on 10-year Treasury bond		Enterprise Value	149
(3) Obtained from PWC market risk study 2010		SALES 2010	69
(4) Obtained from Beta and Capital Structure tab		EBITDA 2010	8
(5) Obtained from PWC market risk study 2010		Implied EV/SALES	2,2x
		Implied EV/EBITDA	18,2x
G D W W 1 Y 2 1 1 D 1 G 1 W			

Source: Dr. Kalliwoda International Research GmbH

b. DCF-Model

				DCF mc	odel	_					
EURm	Actual					CAGR	Forecast period				
	2011	2012	2013	2014	2015	2016	(17 - 20)	2017	2018	2019	2020
Sales	40,1	46,5	52,6	55,9	61,5	69,2	4,1%	75,9	82,4	86,6	89,1
% growth		15,8%	13,0%	6,3%	10,1%	12,4%		9,8%	8,6%	5,1%	2,9%
EBITDA	4,4	5,3	6,3	6,8	5,9	8,2	7%	8,8	9,6	10,7	11,4
% margin	11,0%	11,4%	11,9%	12,2%	9,6%	11,9%		11,6%	11,7%	12,3%	12,8%
Depreciation & Amortization:	-3,5	-1,1	-1,3	-1,3	-1,1	-1,3		-1,2	-1,3	-1,4	-1,4
% sales	8,8%	2,3%	2,5%	2,4%	1,8%	1,9%		1,6%	1,6%	1,6%	1,6%
EBIT	0,9	4,2	5,0	5,5	4,8	6,9	7%	7,6	8,3	9,3	10,0
								10,0%	10,1%	10,7%	11,3%
Taxes	-0,6	-0,2	0,1	-1,0	-0,8	-1,5		-1,5	-1,7	-1,9	-2,0
Capex	-2,2	-0,4	-0,5	-0,6	-0,8	-0,7		-1,0	-1,1	-1,2	-1,1
% sales	5,4%	0,9%	0,9%	1,1%	1,2%	1,0%		1,4%	1%	1%	1%
Increase/Decrease in NWC	-1,26	-1,69	1,21	-1,39	-4,38	2,45		-1,6	-0,2	-0,9	0,4
Unlevered Free Cash Flow	0,38	3,05	7,12	3,75	0,01	8,51		4,59	6,6	6,7	8,6
WACC	6,4%										
Discount Period	.,							1,0	2,0	3,0	4,0
Discount Factor								0,9	0,9	0,8	0,8
Present value of free cash flow							_	4,3	5,9	5,6	6,7

Source: Dr. Kalliwoda International Research GmbH

Equity Research

5. Financial results 6M/2017

TXT reported revenues of € 36.1 million in H1 2017, up +8.9% compared to H1 2016 (€ 33.2 million). The growth was manly driven by revenues from Pace GmbH (€ 1.9 million, acquisition and consolidation since April 1, 2016) and organic growth (+3.7%).

Software revenues from licences, subscriptions and maintenance amounted to \leq 9.0m, higher by +7.4% compared to 6M/2016, while Service revenues equalled at \leq 27.1m which corresponds to increase of +9.4% compared to 6M/2016.

TXT Retail generated € 18.2m, which constituted 504% of group revenues and recorded growth of +2.5% compared to 6M/2016 (previous period: € 17.8m). TXT Retail generated EBITDA of € 1.47m in 6M/17, a margin of 8.1% (vs. the group margin of 9.5%).

The other segment, TXT Next recorded € 17.9m in revenues with significant increase of +16.2%. The segment EBITDA of € 1.95m corresponds to a margin of 10.9%

In terms of profitability, the Company generated €3.3m of EBITDA, while Operating Income equalled at € 2.6m which constitutes decrease by -7.6% compared to 6M/2016. The net income was € 1.6m and was lower by € 0.4m than in 6M/2016.

With regards to Balance Sheet, the company Assets amounted to € 59.4m (previous period: € 62.5m). Total Shareholders' Equity amounted to € 32.3m (previous period: € 34.3m). Net financial position amounted to € 5.47m (previous period: € 5.37m). The company ended6M/17 with net cash of € 5.5m.

On July 24th TXT signed a contract for the inclusion of its TXT Retail Division to Aptos, Inc. (USA). The agreed price of € 85m will be paid in cash by Aptos


Key figures 6M/2017 vs. 6M/2016

6M/2017 vs. 6M/2016			
in EURm	6M/2017	6M/2016	%
Net sales	36.1	33.2	8.7%
EBITDA	3.3	5.9	-44.2%
EBITDA margin	9.1%	17.8%	
EBIT	2.6	2.8	-7.1%
EBIT margin	7.2%	8.4%	
Net income	1.6	2.0	-20%
Net margin	4.4%	6.0%	

Company Analysis

Equity Research

6. Profitability



Source: company data, Dr. Kalliwoda International Research GmbH

7. Outlook

Overall, 6M figures came in strong, with top line being in line with our expectations. Some concerns may raise bottom line of the business in 6M/2017, we expected higher number. However, looking forward, we expect the Company's profit yoy momentum to remains positive for the coming quarters.

Focus on TXT Next with substantial cash on hand, allow the Company to develop aeronautical, the auto industry, transport, and complex industrial systems. We see tremendous potential in these areas. Specifically, we see potential for synergies due to acquisition of PACE in the field of on-board software, flight simulators, and flight training system. Therefore, we regard the deal with Aptos as beneficial for the Company growth.

Over the approaching years, we anticipate continuously raising profit margins, if additional products are successfully migrated to the new software platform.


Due to some uncertainty regarding the closing deal with Aptos, we leave our estimates unchanged, slightly increasing the target price and therefore setting a 12-month target price at EUR 12.30, with upside around 12% at the current price.

Equity Research

8. Shares

At the end of 2016, the company held about 10.4% of issued shares, bought at an average price of €2.44 The holding company 4CV PTE Ltd held 25.6%, followed by the founder A. Braga Illa with 14.0%, Kabouter Management LLC 7.96% (US-based investor), the management 8.1% and the recent participation of Allianz Global Investors GmbH 2.3%.

Shareholders' structure (December, 31 2016)



9. Financials

a. Profit and Loss Statement

Profit & Loss Statement - TXT e-solutions S.p.A.									
€ thousands	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017E			
Total revenue	46,50	52,56	55,88	61,54	69,15	75,93			
Costs of sales	-22,35	-24,85	-26,46	-29,19	-32,04	-33,16			
Gross profit	24,15	27,71	29,43	32,35	37,11	42,77			
Research and development expenses	-4,09	-4,76	-4,70	-5,12	-6,55	-6,81			
Sales, marketing and distribution expenses	-8,98	-10,17	-11,09	-12,68	-13,57	-14,73			
General and administrative expenses	-5,76	-6,51	-6,84	-8,63	-8,77	-12,42			
Amortisation and depreciation	-1,08	-1,31	-1,33	-1,12	-1,31	-1,21			
EBIT	4,24	4,96	5,47	4,79	6,91	7,59			
Financial income/expense net	0,13	-0,44	-0,25	-0,15	0,11	0,11			
Earnings before taxes	4,37	4,52	5,22	4,64	7,01	7,70			
Income taxes	-0,18	0,12	-1,05	-0,76	-1,46	-1,73			
Minorities/Non recurring profit	0,94	0,00	0,00	0,00	0,00	0,00			
Netincome	5,14	4,64	4,17	3,88	5,56	5,97			
EPS	0,94	0,44	0,32	0,30	0,48	0,51			
DPS	0,40	0,20	0,25	0,25	0,27	0,28			
Profit & Loss (Year on Year)									
Total revenue	16%	13%	6%	10%	12%	10%			
Costs of sales	14%	11%	6%	10%	10%	3%			
Gross profit	17%	15%	6%	10%	15%	15%			
Research and development expenses	46%	16%	-1%	9%	28%	4%			
Sales, marketing and distribution expenses	13%	13%	9%	14%	7%	9%			
General and administrative expenses	6%	13%	5%	26%	2%	42%			
Amortisation and depreciation	-69%	21%	1%	-15%	16%	-7%			
EBIT	387%	17%	10%	-12%	44%	10%			
Financial income/expense net	81%	-435%	-43%	-39%	-170%	3%			
Earnings before taxes	364%	3%	15%	-11%	51%	10%			
Income taxes	-70%	-169%	-964%	-27%	91%	19%			
Net income	-64%	-10%	-10%	-7%	43%	7%			
Profit & Loss (% of Revenues)									
Total revenue	100%	100%	100%	100%	100%	100%			
Costs of sales	-48%	-47%	-47%	-47%	-46%	-44%			
Gross profit	52%	53%	53%	53%	54%	56%			
Research and development expenses	-9%	-9%	-8%	-8%	-9%	-9%			
Sales, marketing and distribution expenses	-19%	-19%	-20%	-21%	-20%	-19%			
General and administrative expenses	-12%	-12%	-12%	-14%	-13%	-16%			
Amortisation and depreciation	-2%	-2%	-2%	-2%	-2%	-2%			
EBIT	9%	9%	10%	8%	10%	10%			
Financial income/expense net	0%	-1%	0%	0%	0%	0%			
Earnings before taxes	9%	9%	9%	8%	10%	10%			
Income taxes	0%	0%	-2%	-1%	-2%	-2%			
Net income	11%	9%	7%	6%	8%	8%			

b. Balance Sheet

Bal	ance sheet - TX1	「e-solution	s S.p.A.			
€m	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017E
Current assets	36,77	34,91	34,89	38,95	37,09	39,73
Cash and cash equivalents	15,82	14,82	12,30	9,08	7,57	9,14
Inventories	1,39	1,45	1,82	2,07	3,15	2,48
Trade receivables	17,27	16,84	18,57	25,03	23,74	24,69
Other receivables	2,29	1,80	2,20	2,76	2,63	3,42
(% sales)	5%	3%	4%	4%	5%	5%
Non-current assets	21,84	17,85	18,02	18,13	25,43	25,73
Intangible assets	19,89	15,37	15,08	14,69	21,30	21,18
(% sales)	43%	29%	27%	24%	31%	28%
Property, plant and equipment	1,15	1,12	1,25	1,36	1,60	1,63
Other receivables and other assets	0,30	0,13	0,14	0,14	0,16	0,15
(% sales)	1%	0%	0%	0%	0%	0%
Deferred taxes	0,49	1,23	1,56	1,94	2,37	2,77
(% sales)	1%	2%	3%	3%	3%	3%
Total	58,61	52,76	52,91	57,08	62,51	65,46
Current liabilities	20,65	17,86	17,45	18,35	21,05	20,56
Financial liabilities	5,50	3,35	2,15	0,82	0,81	0,89
Trade payables	1,80	1,50	1,54	1,42	1,63	1,64
Otherliabilities	12,47	12,93	13,61	16,09	17,93	17,84
(% sales)	27%	25%	24%	26%	25%	24%
Taxliabilities	0,89	0,07	0,15	0,02	0,69	0,19
(% sales)	2%	0%	0%	0%	1%	0%
Non-current liabilities	11,77	6,96	6,49	5,10	7,18	7,92
Financial liabilities	4,30	2,90	1,68	0,00	1,39	1,29
Otherliabilities	2,87	0,00	0,00	0,00	0,00	0,00
(% sales)	0%	0%	0%	0%	0%	0%
Provisions for pensions (TFR)	3,33	3,30	3,84	3,83	3,95	4,73
(% sales)	7%	6%	7%	6%	6%	6%
Deferred taxes	1,27	0,77	0,97	1,27	1,84	1,90
Shareholder's equity	26,18	27,94	28,97	33,62	34,28	36,98
Total consolidated equity and debt	58,61	52,76	52,91	57,08	62,51	65,46


c. Cash Flow Statement

	Cash flow statement - TXT e-solutions S.p.A.										
€m	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY2017E					
Net income for the year	5,1	4,6	4,2	3,9	5,6	6,0					
Depreciation	-1,1	-1,3	-1,3	-1,1	-1,3	-1,2					
Change in working capital	-1,7	1,2	-1,4	-5,0	3,1	-1,6					
Others	2,3	0,9	2,4	-0,7	-1,0	-0,5					
Net Operating cash flow	4,7	5,5	3,8	6,7	8,8	7,3					
Cash flow from investing	-14,7	-0,5	-0,6	-0,8	-0,7	-1,0					
Free cash flows	-10,0	5,0	3,2	6,0	8,1	6,2					
Cash flow from financing	11,4	-6,3	-5,6	-9,2	-3,8	-4,7					
Change in cash	1,4	-1,3	-2,4	-3,2	-1,1	1,6					
Cash, start of the year	14,4	15,8	14,8	12,3	9,1	7,6					
Cash, end of the year	15,8	14,8	12,3	9,1	7,6	9,1					

Source: company data, Dr. Kalliwoda International Research GmbH

d. Financial Ratios

Ratios - TXT e-solutions S.p.A.						
	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017E
EBITDA margin	11,4%	11,9%	12,2%	9,6%	11,9%	11,6%
Net margin	11,0%	8,8%	7,5%	6,3%	8,0%	7,9%
Return on equity (ROE)	19,6%	16,6%	14,4%	11,5%	16,2%	16,1%
Return on assets (ROA)	10,1%	9,1%	8,4%	7,3%	9,1%	9,2%
Return on capital employed (ROCE)	20,2%	27,0%	36,4%	30,8%	33,3%	36,1%
Equity ratio	44,7%	52,9%	54,8%	58,9%	54,8%	56,5%
Current ratio	1,8	2,0	2,0	2,1	1,8	1,9
Quick ratio	1,6	1,8	1,8	1,9	1,5	1,6



Source: Company data, Dr. Kalliwoda Research GmbH

Contacts

Primary Research Fair Value Analysis International Roadshows		Dr. Kalliwoda International Research GmbH, Steinstraße 24, D-64839 Münster, office Frankfurt Arndtstr. 47, 60325 Frankfurt Tel.: 069-97 20 58 53 Fax: 069-13 81 92 15		
Head:	CEFA-Analyst; University of	Sectors: IT, Software, Electricals & Electronics,		
Dr. Norbert Kalliwoda	Frankfurt/Main; PhD in Economics;	Mechanical Engineering, Logistics, Laser,		
E-Mail: nk@kalliwoda.com	DiplKfm., DiplHdl.	Technology, Raw Materials		
Dr. Peter Arendarski	Senior-Analyst, Msc & Ph.D in	Sectors: Technology, Raw Materials, Banks &		
E-Mail: pa@kalliwoda.com	Finance (Poznan Univers. of	Insurances, Financial-Modelling (Quant.,		
E-Mail. pa@kailiwoda.com	Economics), CFA Level 3 Candidate			
D. I.I.D. II		Buyside)		
Patrick Bellmann	Junior-Analyst; WHU - Otto Beish.	Sectors: Support Research and Quantitative		
E-Mail: pb@kalliwoda.com	School of Management Vallendar	Approach		
Ilias Chahboune	Master Economics: Uni Amsterdam	Sectors: Consumer, Retail, Real Estate		
E-Mail: ic@kalliwoda.com				
Kilian Dreher	Junior-Analyst; University of	Sectors: Consumer, Retail, Food & Beverages,		
E-Mail: kd@kalliwoda.com	Frankfurt/Main	Fashion		
Michael John	DiplIng. (Aachen)	Sectors: Chemicals, Chemical Engineering, Basic		
E-Mail: mj@kalliwoda.com	Dipi. ing. (riuciicii)	Metals, Renewable Energies, Laser/Physics		
Marta Kifleab	University of Mainz:	Roadshow/Conference Organisations		
		Koadshow/Conference Organisations		
E-Mail: mki@kalliwoda.com	Sprachwissenschaften	G , ITD ITD G , T , T , T , T , T , T , T , T , T ,		
Rainer Koch	Computer-Science/DiplBetriebw,	Sectors: IT, IT-Services, Internet, Media, Internet,		
E-Mail: rk@kalliwoda.com	(Frankfurt); seasoned international	Emerging Markets		
	Executive IT-Industry			
Witold Konrad Kosinski	Finance & Banking Warsaw School of	Sectors: Consumer Goods, Trading Companies,		
E-Mail: wk@kalliwoda.com	Econ, Master of Science; postgrad.	Food & Beverages, Technology		
	Managem.Studies,Prepar.CFA Lev.2	<i>2 </i>		
Olaf Köster	DiplBetriebswirt, EBS	Sectors: Renewable Energy/Technology		
E-Mail: ok@kalliwoda.com	Dipli Demices with EDS	<u>sectors</u> . Items was a margy realisting		
Sebastian Krawczyk	Bachelor in Management, Quant.	Sectors: Quantitative Methods, Automotive,		
E-Mail: sk@kalliwoda.com	Meth. in Economics & Inf. Systems at	Technology		
E-Maii. Sk@kaiiiwoda.com		Technology		
Charles and T. 200-1	Warsaw School/Mannheim, CFA Can.	C · F' 'I D IF · ·		
Christoph Löffel	Bachelor Betriebswirtschaftslehre	Sectors: Financials, Real Estate		
E-Mail: cl@kalliwoda.com	Universität Mannheim			
Vittoria Lou D. Mawis	Architect; University Barcelona	Sectors: Assistant Office & Real Estate Research		
E-Mail: cl@kalliwoda.com				
Dr. Christoph Piechaczek	DiplBiologist; Technical University	C 4 D' 4 1 0 II 1/1 N/ 1' 1		
EM 1 GI III 1		Sectors: Biotech & Healthcare; Medical		
E-Mail: cp@kalliwoda.com	Darmstadt; Univ. Witten-Herdecke.	Technology Pharmaceutical		
E-Mail: cp@kalliwoda.com Nele Rave	Darmstadt; Univ. Witten-Herdecke. Lawyer; Native Speaker, German			
		Technology Pharmaceutical		
Nele Rave E-Mail: nr@kalliwoda.com	Lawyer; Native Speaker, German School London,	Technology Pharmaceutical Legal adviser		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt;	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main.	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg.	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg.	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and Business Administration (Goethe	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele E-Mail: rw@kalliwoda.com	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and Business Administration (Goethe University Frankfurt M.)	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele E-Mail: rw@kalliwoda.com	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and Business Administration (Goethe University Frankfurt M.) Analyst of this research:	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele E-Mail: rw@kalliwoda.com	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and Business Administration (Goethe University Frankfurt M.)	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele E-Mail: rw@kalliwoda.com Also view Sales and Earnings Estimates:	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and Business Administration (Goethe University Frankfurt M.) Analyst of this research:	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele E-Mail: rw@kalliwoda.com Also view Sales and Earnings Estimates: DR. KALLIWODA	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and Business Administration (Goethe University Frankfurt M.) Analyst of this research:	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele E-Mail: rw@kalliwoda.com Also view Sales and Earnings Estimates: DR. KALLIWODA RESEARCH on Terminals of	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and Business Administration (Goethe University Frankfurt M.) Analyst of this research:	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele E-Mail: rw@kalliwoda.com Also view Sales and Earnings Estimates: DR. KALLIWODA	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and Business Administration (Goethe University Frankfurt M.) Analyst of this research:	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		
Nele Rave E-Mail: nr@kalliwoda.com Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com Dr. Erik Schneider E-Mail: es@kalliwoda.com Hans-Georg Sutter E-Mail: hsu@kalliwoda.com Rainer Wochele E-Mail: rw@kalliwoda.com Also view Sales and Earnings Estimates: DR. KALLIWODA RESEARCH on Terminals of	Lawyer; Native Speaker, German School London, DiplGeophysicists; University of Frankfurt/Main. DiplBiologist; Technical University Darmstadt; Univ. Hamburg. DiplWirtschaftsingenieur University Kaiserslautern Bachelor of Science in Economics and Business Administration (Goethe University Frankfurt M.) Analyst of this research:	Technology Pharmaceutical Legal adviser Sectors: Oil, Regenerative Energies, Specialities Chemicals, Utilities Sectors: Biotech & Healthcare; Medical Technology Pharmaceutical Sectors: IT/e-commerce		

Disclaimer

Company Analysis

Essential information, disclosures and disclaimer

A. Essential information

The investments in financial instruments and securities (e.g. equities, bonds) generally involved on high risks. It is possible that the investors lose some or all of the invested money. Potential investors should be aware of the fact that the prices of securities could fall and rise. The income from such an_investment might be considerable fluctuations. Investment strategies are not appropriate at all times and past results are not a guarantee for the future performance. Investors should make their own and independent decisions as to whether a risky investment.

B. Disclosures according to Section 34b of the German Securities Trading Act (WpHG) and to the German Regulation governing the Analysis of Financial Instruments (FinAnV).

I. Information about author, company held accountable, regulatory authority:

Company responsible for the content of this document: DR. KALLIWODA RESEARCH GmbH, Frankfurt am Main, Germany.

Regulatory authority for DR. KALLIWODA RESEARCH GmbH is the Federal Financial Supervisory Authority (BaFin), Graurheindorfer Straße 108, 53117 Bonn, Germany and Lurgiallee 12, 60439 Frankfurt am Main, Germany.

Author of this research: Dr. Norbert Kalliwoda, Analyst, CEO and founder of DR. KALLIWODA RESEARCH GmbH.

II. Additional Information:

1. Sources of information:

Essential sources of information for the compilation of this document are publications from domestic and international information services and media (e.g. Bloomberg, dpa-AFX, Reuters, VWD, among others), financial press (e.g. Allgemeine Zeitung Frankfurter, Börsenzeitung, Financial Times Handelsblatt and others), specialized trade press, published statistics, rating agencies as well as publications by peer group companies and the company itself. Additionally, conservation has been held with the management of the company. This document was made available to the company before publishing to ensure the correctness of the information provided.

2. Summary of the basis of valuation principles and methods used to prepare this document:

Within the scope of the evaluation of companies the following valuation methods are applied: Multiple-based models (Price/Earnings, Price/Cash-flow, Price/Book value, EV/Sales, EV/EBIT, EV/EBITDA), peer group comparisons, historic valuation methods, discounting models, sum-of-the-parts-approaches, substance-valuation methods and swot-analyses. The valuation principles and models are dependent on macroeconomic factors, such as interest rates, exchange rates, raw materials and on basic assumptions about the economy. Besides, the market moods and market sentiment affects the valuation of enterprises. The approaches are based on expectations that could change rapidly and without advance warning according on developments specific to individual branch. The valuation results and fair values derived from the models might therefore change accordingly.

The ratings are the evaluation results and refer to a fair value pricing reflecting a time-horizon of up general relate to a twelve-months. Nevertheless, evaluation results are subject to changing market conditions and constitute merely a snapshot. The evaluation results and fair values may be reached faster or slower than expected by the analysts. The results and fair values may to be scale upwards or downwards.

DR. KALLIWODA RESEARCH GmbH uses the following rating model:

BUY:	Based on our analysis, we expect the stock to appreciate and produce a total return of at least 10% over the next twelve months
ACCUMULATE:	Based on our analysis, we expect the stock to appreciate and produce a total return between 5%-10% over the next twelve months
HOLD:	Based on our analysis, we expect the stock to produce a total return between -5% and +5% over the next twelve months
REDUCE:	Based on our analysis, we expect the stock to cause a negative return between - 5% and -10% over the next twelve months
SELL:	Based on our analysis, we expect the stock to cause a negative return exceeding - 10% over the next twelve months

3. Date of first publication of this document: 21nd of September 2017

4. Updates:

A specific update of this document has currently not been set. The research reflects the author's judgement on the date of this publication and is subject to change without any notice. The document might be incomplete or reduced and it may not contain all information concerning the company covered. It is in the sole decision of DR. KALLIWODA RESEARCH GmbH whether and when a potential update of this research is made.

III. Disclosures about potential conflicts of interest:

The business model of DR. KALLIWODA RESEARCH GmbH is based on economic relationships with issuer company and equity transactions to be performed relating to the issuer's stock. Dr. Kalliwoda Research has entered into an agreement about the creation of this document with the company which is, or whose financial instruments are the issue of this research.

Conflicts of interest may be in existence with employees of DR. KALLIWODA| RESEARCH GmbH who are the authors of this document as well as other persons that were involved in the preparation of this research or related parties.

Following conflicts of interest might exist:

- DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this
 document or related parties might have a major shareholding (holding more than 5%) of the share capital of the emitter
 that is, or whose financial instruments are, the subject of the research.
- 2. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties are possibly holders of instruments that are mentioned in this research (or that are linked to these instruments) or might become holders and could regularly trade the emitter's securities or securities based on these issues as principal or agent.
- 3. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties could have participated in leading a consortium for the emitter via a public offering of the financial instruments that are the subject of this research.
- 4. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties might have been party to an agreement on the provision of investment banking services with the emitter which is the subject of this research, or have received services or a pledge to perform under the terms of such an arrangement during the same period.
- 5. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties may have other substantial economic interests concerning to the emitter which is the subject of this research.
- 6. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties might have been party to an agreement with the company, which is the subject of this research, resulting in receiving the compensation for preparation of this research.
- 7. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties received the feedback concerning the company profile and SWOT from the company, which is the subject of this research, before publishing this report to the public.

Important: Please get familiar with possible risks and possible conflicts of interest in the disclosure and disclaimer at the end of this report, especially for this report:

6. and 7.

The analysts have limited access to gain information that possibly could constitute a conflict of interest for the institution DR. KALLIWODA RESEARCH GmbH keeps insider registers appropriate to sec. 15 WpHG for assignees that normally have approach to inside information. Insiders' dealings appropriate to sec. 14 WpHG categorically are prohibited.

The analysts that composed this research did not receive or acquire shares in the emitter that is the subject of this document at any time. The analysts mentioned above herby certify that all of the views expressed accurately reflect the individual views about the emitter. No part of the indemnity was, is or will be, directly or indirectly, linked to the evaluation result or views expressed by the analyst in this research.

C. Disclaimer:

This document is published and being distributed by DR. KALLIWODA RESEARCH GmbH solely for informational purposes and for the personal use by persons in Germany. This research is not intended to be in any form an offer or advice to buy or sell the securities referred to herein. This research is intended to provide information to assist investors in making their own investment decisions. Any decision to purchase any securities of the emitter must be made solely on the basis of the information contained in the offering documents from the emitter relating to such securities and not on the contents hereof. Furthermore, our recommendation may not be fully suitable to every investor, depending on their investment objective, individual financial situation or targeted holding period.

Potential investors should seek professional and individual information and advice before making their investment decisions. This document neither constitutes a contract or any kind of obligation.

Neither this document nor any copy, in whole or in part, thereof may be distributed in any other jurisdiction where its distribution might be restricted by law, and person into whose published this document comes should inform and observe themselves about any such restrictions.

The information within this document has been obtained from sources believed by DR. KALLIWODA RESEARCH GmbH to be reliable. DR. KALLIWODA RESEARCH GmbH does not examine the information to be verify and complete, nor warrantees its correctness and completeness. Although due attention has been taken in compilation this document, it cannot be excluded that the information given is not complete or the document contains mistakes.

The liability of DR. KALLIWODA RESEARCH GmbH shall be restricted to gross negligence and wilful misconduct. All aspects penned in this document are those of DR. KALLIWODA RESEARCH GmbH respectively the authors and subject to modify without notice. Possible faults or incompleteness of this document may be reformed by DR. KALLIWODA RESEARCH GmbH and do not constitute reasons for liability, neither with regard to indirect nor to direct or consequential losses.

Moreover, DR. KALLIWODA RESEARCH GmbH does not accept any responsibility and liability for any damage arising from using of this research or its contents or otherwise arising in relation herewith. In each case, the liability and responsibility of DR. KALLIWODA RESEARCH GmbH is limited to typical, predictable damages and the liability for any direct or indirect losses is excluded.

This document is subject to the laws of the Federal Republic of Germany. Place of jurisdiction is Frankfurt am Main, Germany.

This document or any copy, in whole or in part thereof, may be distributed in any other jurisdiction where its distribution might be restricted by law and persons who have access to this document have to inform and observe themselves about any such restrictions.

In the United Kingdom this document is to be distributed only to persons who are described in Section 11 (3) of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order 1996 (as amended). This research may not be distributed and forwarded directly or indirectly to any other group of individuals. The distribution of this document in other international jurisdictions may be restricted by law and individuals who possess this study should inform themselves of any existing restrictions and comply with them.

Neither this document nor any copy of it may be taken or transmitted into the United States of America, Canada, Japan or Australia or distributed, directly or indirectly, in the United States of America, Canada, Japan or Australia or to any resident thereof. Any Failure to comply with these restrictions may constitute a violation of United States, Canadian, Japanese or Australian securities laws or the law of any other jurisdiction.

By confirming this document the reader or user agrees and accepts to be bound by all of the foregoing provisions and this disclaimer. Besides, the user accepts not to distribute this document to unauthorized persons. The user of this document compensated DR. KALLIWODA RESEARCH GmbH for any disadvantages, damages, claims and losses resulting from or in relation with the unauthorized use of this document.

© 2017 DR. KALLIWODA RESEARCH GmbH, Steinstr. 24, D-64839 Münster und Arndtstraße 47, D-60325 Frankfurt am Main. All rights reserved.